It sometimes seems like weight loss drugs are being grasped as the answer to all society’s troubles — including, with UK plans to trial them in the unemployed, worklessness.
But there are good reasons to think the class of drugs known as GLP-1s, including Novo Nordisk’s Ozempic and Eli Lilly’s Zepbound, could be used in therapeutic areas that extend beyond obesity and diabetes.
The latest is a study suggesting such drugs reduce opioid and alcohol addiction by up to half. GLP-1s are being tested on patients with Alzheimer’s, on top of conditions that can often go hand-in-hand with obesity.
您已阅读21%（595字），剩余79%（2179字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。